IL-2 therapy in type 1 diabetes: “Trials” and tribulations
Author:
Publisher
Elsevier BV
Subject
Immunology,Immunology and Allergy
Reference57 articles.
1. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus;Herold;N. Engl. J. Med.,2002
2. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes;Keymeulen;N. Engl. J. Med.,2005
3. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function;Pescovitz;N. Engl. J. Med.,2009
4. Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial;Orban;Lancet,2011
5. The biology of interleukin-2;Malek;Annu. Rev. Immunol.,2008
Cited by 49 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. DRAK2 contributes to type 1 diabetes by negatively regulating IL-2 sensitivity to alter regulatory T cell development;Cell Reports;2023-02
2. Particle-Based therapies for antigen specific treatment of type 1 diabetes;International Journal of Pharmaceutics;2023-01
3. Costimulation blockade in combination with IL-2 permits regulatory T cell sparing immunomodulation that inhibits autoimmunity;Nature Communications;2022-11-09
4. The long and winding road: From mouse linkage studies to a novel human therapeutic pathway in type 1 diabetes;Frontiers in Immunology;2022-07-22
5. Emerging Therapeutics for Immune Tolerance: Tolerogenic Vaccines, T cell Therapy, and IL-2 Therapy;Frontiers in Immunology;2021-03-29
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3